Carvedilol ameliorates persistent erythema of erythematotelangiectatic rosacea by regulating the status of anxiety/depression

摘要

Abstract The treatment of persistent erythema and rosacea flushing is extremely challenging, especially for patients with anxiety. The aim of this study was to verify the efficacy of carvedilol in rosacea patients with persistent erythema and flushing. A total of 156 patients were randomized to use oral carvedilol 5?mg bid (twice per day) (n?=?105) or topical brimonidine (n?=?51) for a 10‐week period with 6?weeks of follow‐up. Both the efficacy of carvedilol and the status of anxiety/depression were analyzed by patient self‐assessment (PSA), clinician erythema assessment (CEA), generalized anxiety disorder (GAD‐7), and patient health questionnaire‐9 (PHQ‐9). Our study found that carvedilol exerted a dramatic reduction in CEA/PSA scores and sting/burning sensation scores in comparison to topical brimonidine. Additionally, carvedilol treatment dramatically improved telangiectasia, erythema, and pigmentation with no obvious side effects. Patients with carvedilol treatment showed an improvement of depression/anxiety, as reflected by lower GAD‐7 and PHQ‐9 scores than patients with topical brimonidine. Notably, we found carvedilol treatment had better outcomes among patients under 30?years of age with rosacea younger than 30?years old. Conclusively, our findings reveal that carvedilol could quickly and effectively improve facial erythema, which might stem from the improved the status of anxiety/depression.